P Pu ur rp po os se e: : To compare the hemodynamic effects of dopamine with those of dobutamine when administered with milrinone in patients undergoing non-cardiac surgery.
; each hemodynamic variable was measured 20 min after changing the infusion rate. One hour after ceasing the infusion of one catecholamine (dopamine or dobutamine), the other was infused at the rate of 4 and 8 µg·kg R Re es su ul lt ts s: : Milrinone increased heart rate (HR), but decreased mean arterial pressure (MAP) and systemic vascular resistance (SVR) (P < 0.05 for each). Dopamine administered with milrinone significantly increased MAP and cardiac output (CO), whereas dobutamine significantly increased HR and CO, but decreased SVR. By comparison between dopamine and dobutamine administered at the rate of 8 µg·kg , there was a significant difference in HR, MAP, and SVR (P < 0.01, 0.01, and 0.05, respectively).
C Co on nc cl lu us si io on n: : Dopamine and dobutamine administered with milrinone induce different hemodynamic changes: dopamine increases MAP without affecting HR, whereas dobutamine increases HR. Our data suggest that the myocardial oxygen balance might be better preserved with dopamine than with dobutamine when administered with milrinone. 8 Furthermore, combined administration of dobutamine and milrinone has been recommended to induce beneficial additive effects in heart failure. 9 However, combined administration of dobutamine and milrinone reduces mean arterial pressure (MAP) and increases heart rate (HR), 10 which can cause myocardial ischemia in patients with coronary artery disease. Conversely, norepinephrine combined with amrinone is effective for maintaining systemic blood pressure during aortocoronary graft surgery.
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Dopamine stimulates dopaminergic receptors at low doses, and at somewhat higher doses, exerts a positive inotropic effect on the myocardium through ß 1 -adrenergic receptors, but tachycardia is less prominent during infusion of dopamine than of isoproterenol. 12, 13 At high doses, dopamine activates vascular α 1 -adrenergic receptors, leading to vasoconstriction. 13 Therefore, dopamine might also be beneficial for maintaining blood pressure during infusion of phosphodiesterase-III inhibitors. Although there are a few reports assessing combination therapy with dobutamine and milrinone, 9 the hemodynamic effect of combination therapy with dopamine and milrinone is poorly documented. In the present study, the hemodynamic effects of dopamine were compared with those of dobutamine when administered with milrinone in 14 patients during anesthesia. P Pa at ti ie en nt ts s a an nd d m me et th ho od ds s The study was approved by the Ethics Committee of the National Defense Medical College. Sixteen patients (ASA physical status I to III; nine men and seven women) undergoing elective surgery for carcinoma of the liver, bile duct, or pancreas were enrolled in the study. None of the patients had a history of cardiac disease or preoperative electrocardiogram, chest x-ray, or ultrasonic cardiograph abnormalities. Written informed consent was obtained from all patients. The patients were premedicated with atropine (0.5 mg) and hydroxyzine (50 mg) intramuscularly 30 min before the start of anesthesia. Before inducing anesthesia, an epidural catheter was inserted, and 1.5% mepivacaine was administered through the catheter to avoid nociceptive stimulation at skin incision; however, additional mepivacaine was not used before the end of the study. Anesthesia was induced with propofol (1.0-2.0 mg·kg -1 ) and vecuronium bromide (0.1 mg·kg -1 ), and the trachea was intubated. The lungs were ventilated mechanically and anesthesia was maintained with 3 L·min -1 nitrous oxide and 3 L·min -1 oxygen supplemented with isoflurane (0.8 to 1.5%), the concentration of which was not altered during the study. Acetate Ringer's solution was infused at the rate of approximately 10 mL·kg -1 ·hr -1 , but additional colloidal solution was not given during the investigation. After induction of anesthesia, a pulmonary arterial catheter was introduced via the right internal jugular vein. HR, MAP and systolic arterial pressure (SAP), central venous pressure (CVP), CO, and pulmonary capillary wedge pressure (PCWP) were measured.
When hemodynamics had stabilized after the start of the surgical procedure, hemodynamic values were measured as baseline values before administration of milrinone. Milrinone (50 µg·kg -1 ) was then injected over ten minutes as a loading dose, followed by a continuous infusion of 0.25 µg·kg ) were also assessed to compare the effect of dopamine and dobutamine administered with milrinone.
Statistical analysis
Data are presented as number of patients or mean ± standard deviation (SD). Two-way analysis of variance (ANOVA) for repeated measurements was used to assess changes between groups and one-way ANOVA was used to compare raw data over time within groups. Post hoc analysis to allow for multiple comparisons was performed using a Bonferroni/Dunn correction. Student's t test was used to make single comparisons. Proportional data were evaluated using the Chi square test. A P value of less than 0.05 was considered statistically significant. R Re es su ul lt ts s Patient characteristics are summarized in Table I . Data of two patients whose sequence of infusion was dobutamine followed by dopamine were discarded because the surgical procedures ended before completion of the study. Changes in hemodynamics after infusion of milrinone are shown in Table II . There was no significant difference between hemodynamic values measured after ceasing administration of the first and second catecholamine (Mil-1 and Mil-2, respectively).
There was no significant difference in any hemodynamic baseline value between the dopamine and dobutamine groups (Figure) . Increasing the dose of dopamine to 8 µg·kg -1 ·min -1 did not change HR, MPAP CVP, or PCWP, but increased MAP and CO (P < 0.001 by ANOVA) for each when administered with milrinone. Dobutamine administered with milrinone significantly increased HR (P < 0.0001 by ANOVA). Dobutamine at the rate of 4, but not 8 µg·kg -1 ·min -1 slightly increased MAP (P < 0.05) but CVP was not significantly affected by dobutamine. Although dobutamine slightly decreased PCWP (P < 0.05), it significantly increased CO.
The HR following administration of 8 µg·kg -1 ·min -1 dobutamine was higher than that following administration of 8 µg·kg Increasing the dose of dopamine and dobutamine significantly increased the RPP ( Figure G) ; however, there was no significant difference between the two groups. The PRQ increased with increasing doses of dopamine, whereas it decreased with increasing doses of dobutamine (Figure H) . D Di is sc cu us ss si io on n In the present study, dopamine administered with milrinone increased MAP and CO but did not change HR, CVP, PCWP, and SVR. On the other hand, dobutamine administered with milrinone increased HR and CO, but decreased PCWP and SVR. In patients with heart failure, 9,10 the combination of milrinone and dobutamine causes an increase in HR and a fall in PCWP and SVR, which is consistent with our results. During weaning from cardiopulmonary bypass, 11 amrinone combined with norepinephrine maintains an adequate blood pressure. Because a higher dose of dopamine induces vasoconstriction through activating vascular α 1 -adrenergic receptors, 13 it is not unexpected that compared with two afterload reducers given simultaneously (milrinone + dobutamine), the combination of an afterload reducer and enhancer (milrinone and dopamine particularly in α-range) may work better, because of an unacceptable low blood pressure with the former combination. However, the comparative effects of dopamine and dobutamine in combination with phosphodiesterase-III inhibitors remained unclear. Our results show that dopamine and dobutamine administered with milrinone have different effects on HR, MAP, and SVR: dopamine increases MAP without affecting HR, whereas dobutamine increases HR.
Inotropic agents (e.g., ß-adrenergic receptor agonists, phosphodiesterase inhibitors) administered to patients with congestive heart failure increase MVO 2 , and may provoke myocardial ischemia, especially in patients with coronary artery disease. Although the combined administration of dobutamine and milrinone may induce beneficial additive effects in severe heart failure, 9 dobutamine infused with milrinone might worsen the myocardial oxygen balance because this combination increases HR, a major determinant of O 2 consumption. Our results with combined infusion of dobutamine and milrinone are similar to those from studies with hydralazine, which reduces afterload but induces tachycardia, provoking myocardial ischemic events in severe chronic heart failure.
14 Taken together, the combination regimen of dobutamine and milrinone might decrease myocardial oxygenation.
Dopamine combined with milrinone did not change HR from baseline in the present study. Data are expressed as number of patients or mean ± SD. Pre 88 ± 18 74 ± 11 7 ± 2 6 ± 2 9 ± 3 1019 ± 422 Mil-1 97 ± 16* 68 ± 9* 6 ± 2* 7 ± 2* 6 ± 3* 804 ± 291* Mil-2 97 ± 18* 67 ± 7* 6 ± 2 6 ± 2 6 ± 4* 828 ± 241* Data are expressed as mean ± SD. Pre denotes hemodynamic values before administration of milrinone. The hemodynamic values were obtained 50 min after continuous infusion of milrinone (Mil-1). The second data obtained after ceasing administration of the first catecholamine (dopamine or dobutamine) are expressed as
Because the combination increased MAP, an increase in HR might have been suppressed via the baro-reflex. Dopamine might also be effective for the treatment of hypotension caused by phosphodiesterase inhibitors, because higher doses of dopamine increase blood pressure. However, our results are limited to non-cardiac patients. Further studies are needed to elucidate the efficacy of this combination in patients with coronary artery disease. There was no significant difference in RPP, an index of MVO 2 , 15, 16 between dopamine and dobutamine in the present study. On the other hand, the PRQ characterized hemodynamic differences between dopamine and dobutamine administered with milrinone. Despite the preliminary report by Shiraki et al. that a PRQ of less than 1 is associated with myocardial ischemia, 17 the use of PRQ as a predictor of myocardial ischemia is limited, especially when its value is less than 1. 18, 19 In conclusion, when administered with milrinone under anesthesia with isoflurane, dopamine increases MAP and CO without changing HR, whereas dobutamine increases HR and CO. Our results suggest that dopamine preserves the myocardial oxygen balance better than dobutamine when administered with milrinone. R Re ef fe er re en nc ce es s 
